Therefore, our cohort is homogeneous and the diagnostic strategy used to build this cohort (systematical histologic review, immunohistochemistry, and molecular analysis) is relevant
Early research involving retatrutide has shown very high average weight reduction percentages in some participants
Marketsegmentation:Mounjaro=Premium brand positioning(direct Lilly, established, first-mover) Yurpeak=Access brand positioning(Cipla, affordable, community healthcare) This allows Lilly to maintain premium pricing in metros while Cipla captures the price-sensitive semi-urban market.Result: Market expands rather than cannibalizes The Competitive Context(Novo's Problem) Novo Nordisk's Wegovy: Launched 3 months AFTER Mounjaro in India More expensive(17,345-26,050/month vs Mounjaro's 14,000-27,500) Weaker distribution in tier-2/3 markets Now Novo faces: Mounjaro dominating metros(already 80 crore in 6 months) Cipla partnership taking rural/semi-urban Novo's Wegovy getting squeezed #BioPharma #CiplaLilly #Healthcare To view or add a comment, sign in Zealand Pharma is exploring a direct-to-patient (DTP) model for its next obesity drug, alongside traditional insurer channels
Learn more about Trulicity
